Company Description

Arrowsmith Genetics is a preclinical stage precision oncology company exploiting genetics to broaden the therapeutic target repertoire of anti-cancer drugs. Key to the approach is the AGx Mutational Target Mapping (MTM) platform, which optimizes drug targeting strategies, leading to new therapeutic candidates.